Quarterly report pursuant to Section 13 or 15(d)

Supplemental Equity and Accumulated Other Comprehensive Income (Loss) - Changes in Accumulated Other Comprehensive Income (Loss), Net of Tax (Details)

v3.23.1
Supplemental Equity and Accumulated Other Comprehensive Income (Loss) - Changes in Accumulated Other Comprehensive Income (Loss), Net of Tax (Details) - USD ($)
$ in Thousands
 9 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Balance $ 1,701,770  
Balance 1,889,686  
AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]    
Balance 8,069 $ (6,193)
Other comprehensive income (loss) before reclassifications, net of taxes, attributable to Bio-Techne 4,172 7,757
Reclassification from (gain) loss on derivatives to interest expense, net of taxes, attributable to Bio-Techne(1) (1,870) 3,988
Balance 10,371 5,552
Accumulated Foreign Currency Adjustment Attributable to Parent [Member]    
Balance (83,269) (51,098)
Other comprehensive income (loss) before reclassifications, net of taxes, attributable to Bio-Techne (805) (9,599)
Reclassification from (gain) loss on derivatives to interest expense, net of taxes, attributable to Bio-Techne(1)   0
Reclassification of cumulative translation adjustment for Eminence to non-operating income, net of taxes, attributable to Bio-Techne 152  
Balance (83,922) (60,697)
AOCI Attributable to Parent [Member]    
Balance (75,200) (57,291)
Other comprehensive income (loss) before reclassifications, net of taxes, attributable to Bio-Techne 3,367 (1,842)
Reclassification from (gain) loss on derivatives to interest expense, net of taxes, attributable to Bio-Techne(1) (1,870) 3,988
Reclassification of cumulative translation adjustment for Eminence to non-operating income, net of taxes, attributable to Bio-Techne 152  
Balance $ (73,551) $ (55,145)